Targeted Delivery of antimiR-181c by Hypoxia-Responsive Copolymer Nanoparticles to Reverse Diabetes-Impaired Angiogenesis
Project Member(s): Care, A.
Funding or Partner Organisation: Diabetes Australia Research Trust (Diabetes Australia Research Trust (DART) Awards and Research Grants Scheme)
Diabetes Australia Research Trust (Diabetes Australia Research Trust (DART) Awards and Research Grants Scheme)
Start year: 2021
Summary: Diabetic vascular complications are associated with impaired ischaemia-driven angiogenesis. MicroRNAs are powerful targets for multifaceted diseases. We found that miR-181c inhibition rescues diabetes-impaired angiogenesis. This project will determine the efficacy of hypoxia-responsive copolymer nanoparticles to deliver the miR-181c inhibitor (antimiR-181c) to sites of ischaemia, advancing the development of antimiR-181c as a therapeutic agent to stimulate angiogenesis in a diabetic setting.
FOR Codes: Nanomedicine, Expanding Knowledge in the Medical and Health Sciences, Expanding knowledge in the health sciences, Expanding knowledge in Indigenous studies, Expanding knowledge in the biomedical and clinical sciences